Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Tokyo - Delayed Quote JPY

Tsumura & Co. (4540.T)

Compare
4,201.00
+6.00
+(0.14%)
At close: April 4 at 3:30:00 PM GMT+9
Loading Chart for 4540.T
  • Previous Close 4,195.00
  • Open 4,180.00
  • Bid 4,188.00 x --
  • Ask 4,205.00 x --
  • Day's Range 4,143.00 - 4,225.00
  • 52 Week Range 3,316.00 - 5,138.00
  • Volume 332,800
  • Avg. Volume 359,244
  • Market Cap (intraday) 319.042B
  • Beta (5Y Monthly) 0.07
  • PE Ratio (TTM) 11.76
  • EPS (TTM) 357.09
  • Earnings Date May 9, 2025 - May 19, 2025
  • Forward Dividend & Yield 136.00 (3.24%)
  • Ex-Dividend Date Mar 28, 2025
  • 1y Target Est 5,426.00

Tsumura & Co. manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally. The company offers Kampo extract intermediates, granular and prescription Kampo formulations, over-the-counter Kampo medicine, other medications, and herbal bath salts. It offers its products for female problems, proneness to fatigue, skin problems, gastrointestinal problems, obesity, constipation, hemorrhoid, body aches, cold, cough, nasal/throat inflammation, children's sickness, stress, and urinary problems. Tsumura & Co. was founded in 1893 and is headquartered in Tokyo, Japan.

www.tsumura.co.jp

4,138

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 4540.T

View More

Performance Overview: 4540.T

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4540.T
9.39%
Nikkei 225 (^N225)
15.33%

1-Year Return

4540.T
12.00%
Nikkei 225 (^N225)
15.07%

3-Year Return

4540.T
39.41%
Nikkei 225 (^N225)
21.79%

5-Year Return

4540.T
78.19%
Nikkei 225 (^N225)
89.56%

Compare To: 4540.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4540.T

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    319.04B

  • Enterprise Value

    316.35B

  • Trailing P/E

    11.76

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.86

  • Price/Book (mrq)

    1.09

  • Enterprise Value/Revenue

    1.84

  • Enterprise Value/EBITDA

    6.27

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.79%

  • Return on Assets (ttm)

    4.71%

  • Return on Equity (ttm)

    9.25%

  • Revenue (ttm)

    171.79B

  • Net Income Avi to Common (ttm)

    27.12B

  • Diluted EPS (ttm)

    357.09

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    83.05B

  • Total Debt/Equity (mrq)

    25.25%

  • Levered Free Cash Flow (ttm)

    9.14B

Research Analysis: 4540.T

View More

Company Insights: 4540.T

Research Reports: 4540.T

View More

People Also Watch